1. Home
  2. GBIO vs RGC Comparison

GBIO vs RGC Comparison

Compare GBIO & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • RGC
  • Stock Information
  • Founded
  • GBIO 2016
  • RGC 2014
  • Country
  • GBIO United States
  • RGC Hong Kong
  • Employees
  • GBIO N/A
  • RGC N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • RGC Medicinal Chemicals and Botanical Products
  • Sector
  • GBIO Health Care
  • RGC Health Care
  • Exchange
  • GBIO Nasdaq
  • RGC Nasdaq
  • Market Cap
  • GBIO 41.2M
  • RGC 6.6B
  • IPO Year
  • GBIO 2020
  • RGC 2021
  • Fundamental
  • Price
  • GBIO $6.71
  • RGC $18.76
  • Analyst Decision
  • GBIO Buy
  • RGC
  • Analyst Count
  • GBIO 4
  • RGC 0
  • Target Price
  • GBIO $10.67
  • RGC N/A
  • AVG Volume (30 Days)
  • GBIO 39.3K
  • RGC 228.2K
  • Earning Date
  • GBIO 11-05-2025
  • RGC 10-24-2025
  • Dividend Yield
  • GBIO N/A
  • RGC N/A
  • EPS Growth
  • GBIO N/A
  • RGC N/A
  • EPS
  • GBIO N/A
  • RGC N/A
  • Revenue
  • GBIO $21,230,000.00
  • RGC N/A
  • Revenue This Year
  • GBIO N/A
  • RGC N/A
  • Revenue Next Year
  • GBIO N/A
  • RGC N/A
  • P/E Ratio
  • GBIO N/A
  • RGC N/A
  • Revenue Growth
  • GBIO 61.15
  • RGC N/A
  • 52 Week Low
  • GBIO $3.00
  • RGC $0.09
  • 52 Week High
  • GBIO $25.70
  • RGC $83.60
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 65.83
  • RGC 54.26
  • Support Level
  • GBIO $6.08
  • RGC $16.33
  • Resistance Level
  • GBIO $6.48
  • RGC $21.75
  • Average True Range (ATR)
  • GBIO 0.33
  • RGC 1.47
  • MACD
  • GBIO -0.01
  • RGC 0.53
  • Stochastic Oscillator
  • GBIO 83.58
  • RGC 56.13

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About RGC Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

Share on Social Networks: